Bioymifi, a DR5 activator, is primarily used in cancer research and therapy. It works by activating the DR5 receptor, which induces apoptosis in cancer cells. This makes it a valuable tool in studying cell death mechanisms and developing targeted cancer treatments. Its ability to selectively trigger apoptosis in tumor cells while sparing normal cells highlights its potential in creating more effective and less toxic anticancer therapies. Additionally, Bioymifi is used in preclinical studies to evaluate its efficacy in various cancer models, aiding in the discovery of novel therapeutic strategies.